Identification

Name
Cryptenamine
Accession Number
DB00785  (APRD00890)
Type
Small Molecule
Groups
Approved
Description

Cryptenamine is a mixture of closely related hypotensive alkaloids from Veratrum album (Liliaceae). It has been used in the treatment of hypertension but has largely been replaced by drugs with fewer adverse effects. Cryptenamine has a marked and re-producible depressor effect when given intravenously to hypertensive patients, however the mechanism of action is not known.

Synonyms
Not Available
International/Other Brands
Unitensen (MEDA AB)
Categories
UNII
QVO4N8484O
CAS number
1356-18-9
Weight
Not Available
Chemical Formula
Not Available
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

Pharmacology

Indication

For the treatment of hypertension.

Pharmacodynamics

Cryptenamine is a mixture of closely related hypotensive alkaloids from Veratrum album (Liliaceae). It has been used in the treatment of hypertension but has largely been replaced by drugs with fewer adverse effects.

Mechanism of action

Cryptenamine has a marked and re-producible depressor effect when given intravenously to hypertensive patients, however the mechanism of action is not known. Some evidence has suggested that cryptenamine acts in a similar fashion to atropine, which lowers the "rest and digest" activity of all muscles and glands regulated by the parasympathetic nervous system. This occurs because atropine is a competitive inhibitor of the muscarinic acetylcholine receptors (acetylcholine is the neurotransmitter used by the parasympathetic nervous system). Therefore muscarinic acetylcholine receptors will be listed as experimental targets for cryptenamine.

TargetActionsOrganism
AMuscarinic acetylcholine receptor M2
antagonist
Human
AMuscarinic acetylcholine receptor M1
antagonist
Human
AMuscarinic acetylcholine receptor M3
antagonist
Human
AMuscarinic acetylcholine receptor M4
antagonist
Human
AMuscarinic acetylcholine receptor M5
antagonist
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Cryptenamine.Experimental
AcebutololCryptenamine may increase the hypotensive activities of Acebutolol.Approved, Investigational
AcemetacinThe therapeutic efficacy of Cryptenamine can be decreased when used in combination with Acemetacin.Approved, Experimental, Investigational
AlfuzosinAlfuzosin may increase the hypotensive activities of Cryptenamine.Approved, Investigational
AliskirenCryptenamine may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlprenololCryptenamine may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AmbrisentanCryptenamine may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostineCryptenamine may increase the hypotensive activities of Amifostine.Approved, Investigational
AmlodipineAmlodipine may increase the hypotensive activities of Cryptenamine.Approved
AmphetamineAmphetamine may increase the hypotensive activities of Cryptenamine.Approved, Illicit, Investigational
AtenololAtenolol may increase the hypotensive activities of Cryptenamine.Approved
AvanafilAvanafil may increase the antihypertensive activities of Cryptenamine.Approved
BarnidipineCryptenamine may increase the antihypertensive activities of Barnidipine.Approved
BenazeprilBenazepril may increase the hypotensive activities of Cryptenamine.Approved, Investigational
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Cryptenamine.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Cryptenamine.Withdrawn
BepridilCryptenamine may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetaxololBetaxolol may increase the hypotensive activities of Cryptenamine.Approved, Investigational
BethanidineBethanidine may increase the hypotensive activities of Cryptenamine.Approved
BietaserpineBietaserpine may increase the hypotensive activities of Cryptenamine.Experimental
BimatoprostCryptenamine may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololBisoprolol may increase the hypotensive activities of Cryptenamine.Approved
BosentanBosentan may increase the hypotensive activities of Cryptenamine.Approved, Investigational
BQ-123Cryptenamine may increase the hypotensive activities of BQ-123.Investigational
BretyliumCryptenamine may increase the hypotensive activities of Bretylium.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Cryptenamine.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Cryptenamine.Experimental
BupranololCryptenamine may increase the hypotensive activities of Bupranolol.Approved
CadralazineCadralazine may increase the hypotensive activities of Cryptenamine.Experimental
CafedrineCryptenamine may increase the hypotensive activities of Cafedrine.Investigational
CandesartanCryptenamine may increase the hypotensive activities of Candesartan.Experimental
Candesartan cilexetilCryptenamine may increase the hypotensive activities of Candesartan cilexetil.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of Cryptenamine.Experimental
CaptoprilCryptenamine may increase the hypotensive activities of Captopril.Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Cryptenamine.Withdrawn
CarteololCarteolol may increase the hypotensive activities of Cryptenamine.Approved
CarvedilolCryptenamine may increase the hypotensive activities of Carvedilol.Approved, Investigational
CeliprololCryptenamine may increase the hypotensive activities of Celiprolol.Approved, Investigational
ChlorothiazideCryptenamine may increase the hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Cryptenamine.Approved
CicletanineCryptenamine may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilCryptenamine may increase the hypotensive activities of Cilazapril.Approved
ClonidineClonidine may increase the hypotensive activities of Cryptenamine.Approved
CloranololCryptenamine may increase the hypotensive activities of Cloranolol.Experimental
CyclopenthiazideCryptenamine may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclothiazideCyclothiazide may increase the hypotensive activities of Cryptenamine.Approved
DebrisoquinDebrisoquin may increase the hypotensive activities of Cryptenamine.Approved, Investigational
DelaprilCryptenamine may increase the hypotensive activities of Delapril.Investigational
DeserpidineCryptenamine may increase the hypotensive activities of Deserpidine.Approved
DiazoxideDiazoxide may increase the hypotensive activities of Cryptenamine.Approved
DiethylnorspermineCryptenamine may increase the hypotensive activities of Diethylnorspermine.Investigational
DihydralazineDihydralazine may increase the hypotensive activities of Cryptenamine.Approved, Investigational
DiltiazemDiltiazem may increase the hypotensive activities of Cryptenamine.Approved, Investigational
DipyridamoleDipyridamole may increase the antihypertensive activities of Cryptenamine.Approved
DorzolamideCryptenamine may increase the hypotensive activities of Dorzolamide.Approved
DoxazosinDoxazosin may increase the hypotensive activities of Cryptenamine.Approved
EfonidipineCryptenamine may increase the hypotensive activities of Efonidipine.Approved, Investigational
EnalaprilEnalapril may increase the hypotensive activities of Cryptenamine.Approved, Vet Approved
EnalaprilatCryptenamine may increase the hypotensive activities of Enalaprilat.Approved
EndralazineEndralazine may increase the hypotensive activities of Cryptenamine.Experimental
EpanololCryptenamine may increase the hypotensive activities of Epanolol.Experimental
EpoprostenolCryptenamine may increase the hypotensive activities of Epoprostenol.Approved
EprosartanCryptenamine may increase the hypotensive activities of Eprosartan.Approved
FelodipineCryptenamine may increase the hypotensive activities of Felodipine.Approved, Investigational
FenoldopamCryptenamine may increase the hypotensive activities of Fenoldopam.Approved
Ferulic acidCryptenamine may increase the hypotensive activities of Ferulic acid.Experimental
FosinoprilFosinopril may increase the hypotensive activities of Cryptenamine.Approved
FostamatinibFostamatinib may increase the antihypertensive activities of Cryptenamine.Approved, Investigational
FurazolidoneFurazolidone may increase the hypotensive activities of Cryptenamine.Approved, Investigational, Vet Approved
GuanabenzGuanabenz may increase the hypotensive activities of Cryptenamine.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Cryptenamine.Approved
GuanazodineCryptenamine may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineCryptenamine may increase the hypotensive activities of Guanethidine.Approved
GuanfacineGuanfacine may increase the hypotensive activities of Cryptenamine.Approved, Investigational
GuanoclorCryptenamine may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzCryptenamine may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanCryptenamine may increase the hypotensive activities of Guanoxan.Experimental
HarmalineHarmaline may increase the hypotensive activities of Cryptenamine.Experimental
HexamethoniumCryptenamine may increase the hypotensive activities of Hexamethonium.Experimental
HydracarbazineHydracarbazine may increase the hypotensive activities of Cryptenamine.Experimental
HydralazineHydralazine may increase the hypotensive activities of Cryptenamine.Approved
HydrochlorothiazideCryptenamine may increase the hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Cryptenamine.Approved, Investigational
IloprostIloprost may increase the hypotensive activities of Cryptenamine.Approved, Investigational
ImidaprilCryptenamine may increase the hypotensive activities of Imidapril.Investigational
IndapamideCryptenamine may increase the hypotensive activities of Indapamide.Approved
IndenololCryptenamine may increase the hypotensive activities of Indenolol.Withdrawn
IndoraminIndoramin may increase the hypotensive activities of Cryptenamine.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Cryptenamine.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Cryptenamine.Withdrawn
IrbesartanCryptenamine may increase the hypotensive activities of Irbesartan.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Cryptenamine.Approved
IsradipineIsradipine may increase the hypotensive activities of Cryptenamine.Approved, Investigational
KetanserinKetanserin may increase the hypotensive activities of Cryptenamine.Investigational
LabetalolLabetalol may increase the hypotensive activities of Cryptenamine.Approved
LacidipineCryptenamine may increase the hypotensive activities of Lacidipine.Approved, Investigational
LatanoprostLatanoprost may increase the hypotensive activities of Cryptenamine.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Cryptenamine.Approved, Investigational
LinsidomineCryptenamine may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilLisinopril may increase the hypotensive activities of Cryptenamine.Approved, Investigational
LofexidineCryptenamine may increase the hypotensive activities of Lofexidine.Approved, Investigational
LosartanLosartan may increase the hypotensive activities of Cryptenamine.Approved
MacitentanCryptenamine may increase the hypotensive activities of Macitentan.Approved
ManidipineCryptenamine may increase the hypotensive activities of Manidipine.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Cryptenamine.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of Cryptenamine.Approved, Investigational
MethoserpidineCryptenamine may increase the hypotensive activities of Methoserpidine.Experimental
MethyldopaCryptenamine may increase the hypotensive activities of Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Cryptenamine.Approved, Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Cryptenamine.Approved, Investigational
MetipranololCryptenamine may increase the hypotensive activities of Metipranolol.Approved
MetolazoneMetolazone may increase the hypotensive activities of Cryptenamine.Approved
MetoprololMetoprolol may increase the hypotensive activities of Cryptenamine.Approved, Investigational
MetyrosineCryptenamine may increase the hypotensive activities of Metyrosine.Approved
MibefradilCryptenamine may increase the hypotensive activities of Mibefradil.Investigational, Withdrawn
MinaprineMinaprine may increase the hypotensive activities of Cryptenamine.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Cryptenamine.Approved, Investigational
MirodenafilMirodenafil may increase the antihypertensive activities of Cryptenamine.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Cryptenamine.Approved, Investigational
MoexiprilMoexipril may increase the hypotensive activities of Cryptenamine.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Cryptenamine.Approved, Investigational
MoxonidineMoxonidine may increase the hypotensive activities of Cryptenamine.Approved, Investigational
MuzolimineCryptenamine may increase the hypotensive activities of Muzolimine.Experimental
NadololCryptenamine may increase the hypotensive activities of Nadolol.Approved
NaftopidilCryptenamine may increase the hypotensive activities of Naftopidil.Investigational
NebivololCryptenamine may increase the hypotensive activities of Nebivolol.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Cryptenamine.Withdrawn
NicardipineNicardipine may increase the hypotensive activities of Cryptenamine.Approved, Investigational
NicorandilCryptenamine may increase the hypotensive activities of Nicorandil.Approved, Investigational
NiguldipineCryptenamine may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineCryptenamine may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimodipineNimodipine may increase the hypotensive activities of Cryptenamine.Approved, Investigational
NisoldipineNisoldipine may increase the hypotensive activities of Cryptenamine.Approved
NitrendipineCryptenamine may increase the hypotensive activities of Nitrendipine.Approved, Investigational
NitroprussideNitroprusside may increase the hypotensive activities of Cryptenamine.Approved, Investigational
ObinutuzumabCryptenamine may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
OctamoxinOctamoxin may increase the hypotensive activities of Cryptenamine.Withdrawn
OlmesartanOlmesartan may increase the hypotensive activities of Cryptenamine.Approved, Investigational
OmapatrilatCryptenamine may increase the hypotensive activities of Omapatrilat.Investigational
OxprenololCryptenamine may increase the hypotensive activities of Oxprenolol.Approved
PargylinePargyline may increase the hypotensive activities of Cryptenamine.Approved
PenbutololCryptenamine may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentoliniumCryptenamine may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Cryptenamine.Approved, Investigational
PerindoprilCryptenamine may increase the hypotensive activities of Perindopril.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Cryptenamine.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Cryptenamine.Withdrawn
PhenoxybenzamineCryptenamine may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Cryptenamine.Withdrawn
PhentolaminePhentolamine may increase the hypotensive activities of Cryptenamine.Approved
PinacidilPinacidil may increase the hypotensive activities of Cryptenamine.Approved
PindololCryptenamine may increase the hypotensive activities of Pindolol.Approved, Investigational
PirlindolePirlindole may increase the hypotensive activities of Cryptenamine.Approved
PivhydrazinePivhydrazine may increase the hypotensive activities of Cryptenamine.Withdrawn
Platelet Activating FactorCryptenamine may increase the hypotensive activities of Platelet Activating Factor.Experimental
PolythiazideCryptenamine may increase the hypotensive activities of Polythiazide.Approved
PrazosinPrazosin may increase the hypotensive activities of Cryptenamine.Approved
ProcaineProcaine may increase the hypotensive activities of Cryptenamine.Approved, Investigational, Vet Approved
ProcarbazineProcarbazine may increase the hypotensive activities of Cryptenamine.Approved, Investigational
PropranololPropranolol may increase the hypotensive activities of Cryptenamine.Approved, Investigational
QuinaprilCryptenamine may increase the hypotensive activities of Quinapril.Approved, Investigational
QuinineQuinine may increase the hypotensive activities of Cryptenamine.Approved
RamiprilRamipril may increase the hypotensive activities of Cryptenamine.Approved
RasagilineRasagiline may increase the hypotensive activities of Cryptenamine.Approved
RemikirenRemikiren may increase the hypotensive activities of Cryptenamine.Approved
RescinnamineCryptenamine may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Cryptenamine.Approved, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Cryptenamine.Approved, Investigational
RiociguatCryptenamine may increase the hypotensive activities of Riociguat.Approved
RituximabCryptenamine may increase the hypotensive activities of Rituximab.Approved
SafrazineSafrazine may increase the hypotensive activities of Cryptenamine.Withdrawn
SaprisartanCryptenamine may increase the hypotensive activities of Saprisartan.Experimental
SelegilineSelegiline may increase the hypotensive activities of Cryptenamine.Approved, Investigational, Vet Approved
SelexipagCryptenamine may increase the hypotensive activities of Selexipag.Approved
SildenafilSildenafil may increase the antihypertensive activities of Cryptenamine.Approved, Investigational
SitaxentanCryptenamine may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
SpiraprilCryptenamine may increase the hypotensive activities of Spirapril.Approved
TadalafilTadalafil may increase the antihypertensive activities of Cryptenamine.Approved, Investigational
TalinololCryptenamine may increase the hypotensive activities of Talinolol.Investigational
TelmisartanCryptenamine may increase the hypotensive activities of Telmisartan.Approved, Investigational
TemocaprilCryptenamine may increase the hypotensive activities of Temocapril.Experimental, Investigational
TerlipressinCryptenamine may increase the hypotensive activities of Terlipressin.Approved, Investigational
TetrahydropalmatineCryptenamine may increase the hypotensive activities of Tetrahydropalmatine.Investigational
TheodrenalineCryptenamine may increase the hypotensive activities of Theodrenaline.Investigational
TheophyllineTheophylline may increase the antihypertensive activities of Cryptenamine.Approved
TiboloneCryptenamine may increase the hypotensive activities of Tibolone.Approved, Investigational
TicrynafenCryptenamine may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololTimolol may increase the hypotensive activities of Cryptenamine.Approved
TolazolineCryptenamine may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolonidineCryptenamine may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Cryptenamine.Approved
TorasemideTorasemide may increase the hypotensive activities of Cryptenamine.Approved
TrandolaprilTrandolapril may increase the hypotensive activities of Cryptenamine.Approved
TranylcypromineTranylcypromine may increase the hypotensive activities of Cryptenamine.Approved, Investigational
TravoprostTravoprost may increase the hypotensive activities of Cryptenamine.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Cryptenamine.Approved, Investigational
TrichlormethiazideCryptenamine may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrimazosinTrimazosin may increase the hypotensive activities of Cryptenamine.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Cryptenamine.Approved, Investigational
UdenafilUdenafil may increase the antihypertensive activities of Cryptenamine.Approved, Investigational
UnoprostoneCryptenamine may increase the hypotensive activities of Unoprostone.Approved, Investigational
UrapidilUrapidil may increase the hypotensive activities of Cryptenamine.Investigational
ValsartanValsartan may increase the hypotensive activities of Cryptenamine.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Cryptenamine.Approved
VincamineCryptenamine may increase the hypotensive activities of Vincamine.Experimental
VinpocetineCryptenamine may increase the hypotensive activities of Vinpocetine.Investigational
XipamideCryptenamine may increase the hypotensive activities of Xipamide.Experimental
XylometazolineCryptenamine may increase the hypotensive activities of Xylometazoline.Approved, Investigational
YohimbineYohimbine may decrease the antihypertensive activities of Cryptenamine.Approved, Investigational, Vet Approved
ZofenoprilCryptenamine may increase the hypotensive activities of Zofenopril.Experimental
Food Interactions
Not Available

References

Synthesis Reference

Cavallito ,C.J.; US. Patent 2,789,977; April 23,1957; assigned to Innrin, Neisler and Company.

General References
Not Available
External Links
PubChem Substance
46507822
Therapeutic Targets Database
DAP000479
PharmGKB
PA164749510
Wikipedia
Cryptenamine

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
  • Medpointe pharmaceuticals medpointe healthcare inc
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
G-protein coupled acetylcholine receptor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM2
Uniprot ID
P08172
Uniprot Name
Muscarinic acetylcholine receptor M2
Molecular Weight
51714.605 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Jandhyala ML, Buckley JP: Mechanisms of action of cryptenamine. J Pharm Sci. 1968 Sep;57(9):1576-82. [PubMed:5674398]
  4. Jandhyala BS, Buckley JP: Pharmacology and mechanism of action of cryptenamine. J Pharm Sci. 1966 Sep;55(9):888-93. [PubMed:5918523]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM1
Uniprot ID
P11229
Uniprot Name
Muscarinic acetylcholine receptor M1
Molecular Weight
51420.375 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Receptor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM3
Uniprot ID
P20309
Uniprot Name
Muscarinic acetylcholine receptor M3
Molecular Weight
66127.445 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Guanyl-nucleotide exchange factor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM4
Uniprot ID
P08173
Uniprot Name
Muscarinic acetylcholine receptor M4
Molecular Weight
53048.65 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM5
Uniprot ID
P08912
Uniprot Name
Muscarinic acetylcholine receptor M5
Molecular Weight
60073.205 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]

Drug created on June 13, 2005 07:24 / Updated on July 02, 2018 17:24